A double-blind, dose-escalation trial evaluating the safety and immunogenicity of a human papillomavirus (HPV) type 16 (HPV16) L1 VLP vaccine in healthy adults

Trial Profile

A double-blind, dose-escalation trial evaluating the safety and immunogenicity of a human papillomavirus (HPV) type 16 (HPV16) L1 VLP vaccine in healthy adults

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2010

At a glance

  • Drugs Human papillomavirus vaccine (Primary) ; Alum; MF 59
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top